Contents

Search


palbociclib (Ibrance)

Indications: - metastatic breast cancer* in postmenopausal women * doubles time to progression or death [1] * intended for postmenopausal women with estrogen receptor- positive, HER2-negative metastatic breast cancer who have not received endocrine-based therapy * also indicated for recurrent metastatic estrogen receptor-positive, HER2-negative breast cancer after prior aromatase inhibitor therapy [3] * used in combination with letrozole Adverse effects: - bone marrow suppression [2] - leukopenia, neutropenia, anemia, thrombocytopenia - nausea, vomiting, diarrhea - stomatitis - alopecia - fatigue, asthenia, anorexia - peripheral neuropathy - upper respiratory tract infection - epistaxis [2] Mechanism of action: - cyclin-dependent kinase inhibitor (CDK4/CDK6 inhibitor) [1] Notes: - FDA-approved (Feb 2015)

Interactions

drug interactions

Related

abemaciclib (Verzenio)

General

small inhibitory antineoplastic agent (ib drug) cyclin-dependent kinase inhibitor (CDKI, CDKN)

Database Correlations

PUBCHEM correlations

References

  1. Finn RS et al Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18). American Association for Cancer Research. 2014 Annual Meeting. http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3404&sKey=113bcbb9-585d-4939-b5de-99e11e302ef2&cKey=54090e4a-2f25-4594-83b3-37e21e120e6b&mKey=6ffe1446-a164-476a-92e7-c26446874d93
  2. FDA News Release. February 3, 2015 FDA approves Ibrance for postmenopausal women with advanced breast cancer http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm432871.htm
  3. Medical Knowledge Self Assessment Program (MKSAP) 18, American College of Physicians, Philadelphia 2018
  4. Turner NC, Ro J, Andre F et al for the PALOMA3 Study Group. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015 Jul 16;373(3):209-19. PMID: 26030518 Free Article